Tygacil and Temaz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tygacil (tigecycline) and Temaz (temazepam). Common drug interactions include disseminated intravascular coagulation among females and abnormal loss of weight among males.

The phase IV clinical study analyzes what interactions people have when they take Tygacil and Temaz. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Tygacil?

Tygacil has active ingredients of tigecycline. eHealthMe is studying from 2,129 Tygacil users. Check the latest studies of Tygacil.

What is Temaz?

Temaz has active ingredients of temazepam. It is often used in insomnia. eHealthMe is studying from 42,293 Temaz users. Check the latest studies of Temaz.



On Jul, 13, 2026

11 people who take Tygacil and Temaz together, and have interactions are studied.

Tygacil and Temaz drug interactions.

What are the common drug interactions of Tygacil and Temaz, by gender? *:

female:

  1. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  2. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  3. Disease progression
  4. Drug ineffective
  5. Encephalopathy (functioning of the brain is affected by some agent or condition)
  6. Pancreatitis (inflammation of pancreas)
  7. Respiratory failure (inadequate gas exchange by the respiratory system)
  8. Cardiac failure congestive
  9. Death
  10. Febrile neutropenia (fever with reduced white blood cells)

male:

  1. Abnormal loss of weight
  2. Aphagia (inability or refusal to swallow)
  3. Oesophageal carcinoma (cancer tumour of oesophagus)
  4. Oesophageal neoplasm (tumour of oesophagus)
  5. Thrombocytopenia (decrease of platelets in blood)
  6. B-cell lymphoma (blood cancer affecting b cells)
  7. Chest pain
  8. Dysphagia (a condition in which swallowing is difficult or painful)
  9. Hyperhidrosis (abnormally increased sweating)
  10. Nausea (feeling of having an urge to vomit)

What are the common drug interactions of Tygacil and Temaz, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Cardiac failure congestive
  2. Death
  3. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Multi-organ failure (multisystem organ failure)
  6. Sepsis (a severe blood infection that can lead to organ failure and death)
  7. Pericardial effusion (fluid around the heart)
  8. Pneumonia fungal
  9. Renal failure acute (rapid kidney dysfunction)

40-49:

  1. Pulmonary embolism (blockage of the main artery of the lung)

50-59:

  1. Chest pain
  2. Hyperhidrosis (abnormally increased sweating)
  3. Nausea (feeling of having an urge to vomit)

60+:

  1. Abnormal loss of weight
  2. Aphagia (inability or refusal to swallow)
  3. Oesophageal carcinoma (cancer tumour of oesophagus)
  4. Oesophageal neoplasm (tumour of oesophagus)
  5. Thrombocytopenia (decrease of platelets in blood)
  6. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  7. Disease progression
  8. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  9. Drug ineffective
  10. Encephalopathy (functioning of the brain is affected by some agent or condition)

What are the existing conditions these people have? *

  1. Pneumonia: 6 people, 54.55%
  2. The Flu (the flu is caused by an influenza virus): 4 people, 36.36%
  3. Respiratory Tract Infection: 3 people, 27.27%
  4. White Blood Cell Count Abnormal: 2 people, 18.18%
  5. Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 18.18%
  6. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 18.18%
  7. Mycobacterium Chelonae Infection (bacterial infection): 2 people, 18.18%
  8. Cardiac Failure Congestive: 2 people, 18.18%
  9. Wound: 1 person, 9.09%
  10. Richter's Syndrome (hairy cell cancer changes in fast growing b cell cancer tumour): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Tygacil and Temaz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tygacil and Temaz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tygacil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Temaz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tygacil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Temaz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tigecycline and temazepam (the active ingredients of Tygacil and Temaz, respectively), and Tygacil and Temaz (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: